Calibrate's semaglutide membership runs $1,649-$1,999 upfront for a year-long program, with medication billed separately through insurance — a fundamentally different cost model than a monthly medication-focused subscription.
Luma Health's flat semaglutide is $197/month, month-to-month, with no annual commitment required.
Calibrate's pricing looks different from most GLP-1 telehealth providers because it's structured around a year-long clinical program rather than an ongoing monthly medication subscription. Here's what the membership actually includes and costs.
What the Membership Fee Covers
Calibrate's $1,649-$1,999 program fee covers a 12-month "metabolic reset" curriculum: one-on-one coaching across food, exercise, sleep, and emotional health, mandatory baseline and follow-up lab testing, and clinical supervision for insurance-based semaglutide prescribing. As of 2026, Calibrate prescribes brand-name medication (Wegovy) exclusively, having moved away from compounded options amid the broader industry-wide regulatory tightening around compounded GLP-1s.
Medication Is a Separate Cost
The program fee doesn't include semaglutide itself — that's billed through your insurance, with your out-of-pocket cost depending entirely on your specific coverage and copay structure. For patients with good insurance covering Wegovy, this could mean a small monthly copay on top of the program fee; for patients without coverage, brand-name cash-pay cost would be added on top, pushing the total considerably higher.
For an insured patient with a low copay, total first-year cost might land around $1,950-$2,300 (program fee plus 12 months of copays). For an uninsured patient paying cash for Wegovy on top of the program fee, total cost would be considerably higher, potentially exceeding $10,000 for the year given Wegovy's list price.
The Year-Long Commitment
Unlike a month-to-month medication subscription, Calibrate's program fee is paid upfront (or financed) for the full 12-month program, which means early cancellation isn't as simple as stopping a monthly charge. Confirm the specific refund and cancellation terms directly before enrolling, given this upfront structure.
A Month-to-Month Alternative
If a year-long commitment and separate medication billing don't fit your situation, a flat-rate compounded provider offers a simpler month-to-month structure. Luma Health's compounded semaglutide is $197/month, with no annual commitment and no separate medication line item — the price you see includes everything.
Which Model Fits You
- Have insurance covering Wegovy at an affordable copay
- Want intensive year-long coaching and lab monitoring
- Are comfortable with an upfront annual commitment
- Don't have insurance coverage for brand-name Wegovy
- Want flexibility without a year-long commitment
- Prefer one all-inclusive monthly price
No annual commitment,
one flat monthly price
Compounded semaglutide at $197/month, month-to-month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
The program fee has been reported at $1,649-$1,999 for a 12-month program, with semaglutide medication billed separately through insurance.
No. The program fee covers coaching, lab testing, and clinical supervision; semaglutide itself is billed separately through your insurance based on your specific coverage.
Financing options may be available, but the program is structured around a 12-month commitment rather than a simple month-to-month subscription. Confirm current payment options directly.
As of 2026, Calibrate prescribes brand-name Wegovy exclusively, having moved away from compounded options amid broader industry regulatory changes.
Potentially quite high — the program fee plus a full year of cash-pay Wegovy (list price around $1,100-$1,350/month) could exceed $10,000 for the year.
Yes. Flat-rate compounded providers like Luma Health offer month-to-month semaglutide at $197/month, with no annual commitment and no separate medication billing.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com